Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Increased Immunoglobulin G Anti-Paracoccidioides brasiliensis Serum Antibody Avidity as a Predictor of Favorable Posttherapeutic Evolution in Paracoccidioidomycosis

Full text
Author(s):
Yoshida, Marcia [1, 2] ; Arroyo Sanchez, Maria Carmen [3] ; Shikanai-Yasuda, Maria Aparecida [1, 2]
Total Authors: 3
Affiliation:
[1] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Molestias Infecciosas & Parasitarias, Sao Paulo - Brazil
[2] Univ Sao Paulo, Fac Med, Hosp Clin, LIM 48, Sao Paulo - Brazil
[3] Inst Trop Med, Lab Soroepidemiol & Imunobiol, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Clinical and Vaccine Immunology; v. 16, n. 11, p. 1583-1586, NOV 2009.
Web of Science Citations: 1
Abstract

Paracoccidioidomycosis is endemic in Latin America, and ca. 80% of all cases occur in Brazil. Little is known about antibody avidity or the evolution of such avidity in the posttherapeutic period for the different clinical presentations of the disease. In the present study, we evaluated 53 patients with paracoccidioidomycosis and calculated the avidity index. Medium-and high-avidity antibodies were found in 79.5% of patients with chronic presentation (n = 39). Among patients with the acute form (n = 14), 57.1% of the antibodies presented low avidity. In the posttherapeutic period, there was a significant increase in antibody avidity in patients presenting with the chronic multifocal form. In our preliminary study, which needs to be confirmed using a larger number of samples, the optimized method for studying antibody avidity detected differences among the clinical presentations of the mycosis and indicated the value of the avidity index as a marker of posttherapeutic evolution of patients with a multifocal chronic form of the disease. (AU)